<DOC>
	<DOCNO>NCT00999544</DOCNO>
	<brief_summary>Addressing issue opioid dependence tolerance public health implication treatment opioid abuse ( heroin well pharmaceutical opioids ) treatment pain . Recent preclinical data suggest role Substance P ( NK-1 ) receptor modulate acute chronic response opioids . The objective study determine whether pretreatment aprepitant , selective neurokinin-1 ( NK-1 ) antagonist reduce direct response opioid agonist ( oxycodone ) measure relate abuse liability reinforce effect .</brief_summary>
	<brief_title>Aprepitant Effects Oxycodone Response</brief_title>
	<detailed_description>Healthy adult volunteer history illicit opioid use intranasal oral route admit 6-week inpatient , crossover study . They participate 15 experimental test session , last approximately 6.5 hour , receive range acute dose aprepitant , include placebo , follow challenge oxycodone placebo ( give intranasally orally ) . Multi-dimensional outcome , include physiological ( blood pressure , oxygen saturation , pupil diameter ) , subjective ( questionnaire relate mood , abuse liability ) observer rating collect repeatedly throughout session . Data analyze use parametric approach within-subject design .</detailed_description>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<criteria>Recreational user opioids Healthy Ages 1855 year old Able provide inform consent Ongoing medical psychiatric condition would contraindicate participation Past 30 day use P4503A4 inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>opioid</keyword>
	<keyword>oxycodone</keyword>
	<keyword>NK1 antagonist</keyword>
	<keyword>aprepitant</keyword>
	<keyword>intranasal</keyword>
	<keyword>abuse</keyword>
</DOC>